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ABSTRACT
Objective: To assess the long-term risk factors predicting residual/recurrent cervical 
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Design: Retrospective study.
Setting: Colposcopy clinic.
Population: 242 women with CIN 2–3 treated between 1996 and 2006 and followed up until June 
2016.
Methods: Age, margins and high risk-human papillomavirus (HR-HPV) were estimated using 
Cox proportional hazard and unconditional logistic regression models.  The cumulative probability 
of treatment failure was estimated by Kaplan-Meier analysis. 
Main Outcome measure: Histologically confirmed CIN 2-3, HR-HPV, margins, age.
Results: CIN 2-3 was associated with HR-HPV (HR =30.5; 95% CI =3.80-246.20); age >35 years 
(HR =5.53; 95% CI =1.22-25.13);  and margins (HR = 7.31; 95% CI = 1.60–33.44). HR-HPV 
showed a sensitivity of 88.8% and a specificity of 80%. Ecto(+)/endocervical(+)(16.7%), 
uncertain (19.4%) and ecto(-)/endocervical(+) margins (9.1%) showed a higher risk of recurrence 
(OR = 13.20(95% CI =1.02-170.96), 15.84(95% CI =3.02-83.01), and 6.60(95% CI =0.88-49.53)), 
respectively.
Women with involved margins and/or HR-HPV positive had more treatment failure than those 
who were HR-HPV negative or had clear margins (P-log rank<0.001). 
Conclusions: HR-HPV and margins seem essential for stratifying post- LLETZ risk,  and enable 
personalised management. Given that clear margins present a lower risk, a large excision may be 
indicated in older women in order to reduce the risk. 
Funding statement: This study has received no funding.
Keywords: Recurrence, HPV, Margin status, Cervical intraepithelial neoplasia
Tweetable abstract: After LLETZ for CIN 2–3, recurrences appear more often in women with 
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INTRODUCTION
Women with cervical intraepithelial neoplasia 2–3 are treated conservatively, typically by 
large loop excision of the transformation zone (LLETZ) in order to prevent the development of 
invasive cervical cancer (1). After treatment, patients require follow-up because of the risk of CIN 
recurrence or cervical cancer (2) that remains for many years (3)(4).
Several factors are thought to characterise the risk of treatment failure after excisional 
treatment. Age, smoking, size and severity of the lesion, high-risk human papillomavirus (HR-
HPV) type, and persistence of HR-HPV post-treatment have each been shown to predict residual 
or recurrent CIN (5)(6). In addition, margin involvement is a  well-established risk factor for 
treatment failure (7)(8)(9)(10)(11),  However, there are few reports of the prognostic value of HR-
HPV when added to the margin status and site of involvement (10)(12), and long-term follow-up 
data on residual  or recurrent CIN after LLETZ are scarce (13). 
The aim of this study was to assess the clinical outcomes among women treated for CIN2–3 
and followed for a median of 30 months over a 20-year period, to assess the long-term risk of 
CIN2–3 based on HR-HPV status, and surgical margins at baseline.
METHODS
Study Design
This was a retrospective cohort study of consecutive adult women affected by CIN and 
treated by LLETZ at the Department of Gynecology of the Hospital Universitari de Bellvitge 
(Barcelona, Spain). The study was conducted between January 1996 and September 2006, with 
patients followed to June 2016. This gave a maximum follow-up period of 20 years. We included 
patients with a histological diagnosis of CIN 2–3 in the surgical specimen and at least one follow-
up visit after LLETZ. We excluded women with other histological diagnoses, those without 
follow-up data, those who underwent re-excision or hysterectomy immediately after LLETZ, and 
those who were immunosuppressed. 
Patients were not involved in the development of the research. A core outcome set was not 
used when designing the study. However, the Crown database was checked to determine whether a 
relevant core outcome set existed or was in development for this topic, and no such set was found. 
Surgical Procedure
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Lugol’s iodine to the cervical surface. The loop size was chosen based on the tissue to be excised. 
A second selective endocervical sweep was performed with a smaller loop if the transformation 
zone was type 3 or if the patient was older than 35 years. Electrical coagulation was used to 
achieve hemostasis. Specimens were orientated with a stitch for pathological examination.
Follow-up
Follow-up was scheduled at 6 and 12 months after LLETZ, with a Pap smear and 
colposcopy performed at each visit. A sample was taken for HPV detection at 6 months after 
treatment. If surgical margins were positive, the first control visit was scheduled at 3 months. 
Women underwent cervical biopsy if they presented with abnormal cytology results (e.g., atypical 
squamous cells of undetermined significance or worse), a positive HPV result, or an abnormal 
transformation zone at colposcopy. Women with two normal consecutive Pap smear and 
colposcopy results were considered negative for residual or recurrent disease and sent back for 
regular gynaecological control.
The testing procedures for conventional cytology, colposcopy, and HR-HPV were as 
follows. Ecto- and endocervical smears were obtained and the cytology slides were stained using 
the Papanicolaou method for conventional cytology. Cytologic findings were then evaluated 
according to the terminology of the 1989 or 2001 Bethesda System. Colposcopy was performed 
using a Carl Zeiss binocular Colposcope (Jena, Germany) after applying 5% acetic acid to the 
cervix with a cotton ball. An endocervical curettage was performed if the transformation zone was 
not visible (Type 3) or if no abnormality was observed. Specimens were collected for HPV testing 
with the Digene sampler kit (Digene, Gaithersburg, MD, USA), and HPV was identified with the 
HC2 system (Digene). This is a signal-amplified hybridisation antibody capture assay that use 
chemiluminescent detection for each HR-HPV type (16, 18, 32, 34, 36, 39, 45, 51, 52, 56, 58, 59, 
68). The chemiluminescence from the conjugated antibody-hybrid was measured by a 
luminometer as relative light unit (RLU). When the relative light units was greater than or equal to 
the mean of a positive control (1.0 pg/mL), a sample was deemed positive (14).
Criteria for residual/recurrent disease and treatment of recurrence
Residual/recurrent disease was defined as CIN 2–3 diagnosed by cervical biopsy or 
endocervical curettage. CIN 2 and CIN 3 were analysed together due to the anticipated small 
number of cases. Patients affected by residual/recurrent CIN2–3 were referred for a second 
surgical treatment. Residual lesions were defined as those diagnosed within the first year after 
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perform risk assessments to determine whether new CIN2–3 lesions were recurrences or de novo 
infection.
Data Analysis
An electronic case report form was designed in Microsoft Access for prospective data input. 
Follow-up data were retrieved at the end of the study period, and the database was verified to 
evaluate the quality of the collected data. Two-sided P-values <0.05 were considered to indicate a 
significant difference. Data were analysed using Stata software (Release 15.1, StataCorp, USA).
The relationship between categorical variables was assessed by chi-squared tests or 
Fischer’s exact tests, as appropriate. The relationship between continuous and 
categorical variables was assessed by analysis of variance or Kruskal–Wallis tests, as appropriate. 
Predictors of residual/recurrent disease were assessed by estimating odds ratios (ORs) with 95% 
confidence intervals (CIs). We included the following as predictor variables: age (continuous 
variable or dichotomised as ≤35 years and >35 years), parity, smoking status, cervical quadrant 
involved, glandular involvement, margin status, post-LLETZ- HR-HPV status, and 
semiquantitative measure of the viral load (relative light units by HC2) using unconditional 
regression analysis.
We assessed the accuracy of the margin status, first HR-HPV detection, and first cytological 
result after LLETZ by estimating the sensitivity, specificity, positive predicted value (PPV), 
negative predicted values (NPV), positive likelihood of residual/recurrent CIN2–3. The treatment 
failure rate time was calculated from the date of LLETZ to the date of residual/recurrent CIN2–3.
The cumulative probability of treatment failure was estimated by Kaplan–Meier analysis, 
with curves compared using the log-rank test. Univariate Cox proportional hazards models were 
used to explore the effect of margin status, first HR-HPV detection and first cytological result after 
LLETZ as prognostic factors.
Multivariate analysis (logistic analysis or cox proportional model) could not be performed 
due to the small number of cases with residual/recurrent CIN 2-3.  
Funding Statement
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Study Cohort
We enrolled 471 consecutive adult women treated by LLETZ for cervical intraepithelial 
neoplasia or cervical neoplasia. Of these, women were excluded because they had low-grade 
cervical intraepithelial neoplasia  (CIN 1) (n = 140), adenocarcinoma or squamous carcinoma (n = 
2), no follow-up data (n = 26), undergone re-conisation or hysterectomy immediately after LLETZ 
(n = 10), immunosuppression (n = 41), or an unknown immunologic status (n = 10). Finally, 242 
of the 471 eligible cases were included (51.4%). During routine long-term follow-up, HR-HPV 
was determined in 42 cases. The flow chart for study participation is shown in Figure S1 
(Supporting Information). 
The patient characteristics are summarised in Table 1. The median follow-up time was 30 
months (range, 2–257 months), with 75% of patients followed for over 149 months. The median 
age of the population was 35 years (range, 18–77 years).
The indications for the LLETZ procedure were: cervical biopsy with CIN 2-3 in 155 cases 
(64%), persistent CIN 1 in 45 cases (18,6%), discordance Pap smear-biopsy in 25 cases (10,3%); 
carcinoma in one case (0,4%), adenocarcinoma in situ, one case (0,4%). unknown, 15 cases 
(6,2%).
Treatment Success and Residual or Recurrent CIN2–3
In general, LLETZ was highly successful, with 94.6% of cases having no signs of residual 
or recurrent CIN 2-3 during follow-up. This reached 99.1% for cases that were completely 
excised. Residual or recurrent CIN2–3 after LLETZ occurred in 13 cases (5.3%).  One invasive 
squamous cervical carcinoma and one vulvar cancer were detected during follow up. There were 
no cases of adenocarcinoma in situ, but 35 patients (14.4%) developed CIN1.
 The median lag time between LLETZ and residual or recurrent CIN2–3 was 13 months 
(range, 3–212 months; interquartile range, 11–51 months). Five (38.4%) and two (15.3%) CIN2–3 
cases were diagnosed during the first and second year, respectively. Another two were diagnosed 
between 24 and 29 months (15.38%), and four were diagnosed from 30 months onward (30.7%).
Our cohort included 77 cases of CIN 2 (3 CIN 2-3 recurrences) 122 cases of CIN 3 (5 
recurrences), and 43 cases of CIN 2-3 (5 recurrences). No differences were found in the proportion 
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Residual or recurrent CIN was: CIN 3 or CIN 3 with CIN 2 areas in 8 cases (61.5%), CIN 2 
in 3 cases (23.1%) and CIN 2-3 in 2 cases (15.4%).  All 13 cases with residual/recurrent CIN 2–3 
required new treatment: seven underwent repeat LLETZ procedure (53.8%), five underwent 
hysterectomy (38.6%), and one was lost to follow-up (7.6%).
Predictors of Treatment Failure in Patients with CIN2–3 Disease
Factors associated with treatment failure are summarised in Table 1. Treatment failure was 
statistically more frequent among women older than 35 years (P = 0.020) and among those with 
more than four live births (P = 0.016). HR-HPV post LLETZ was positive in 42 cases (23.5%). 
Post-LLETZ HR-HPV positivity was associated with more residual or recurrent CIN 2–3 than 
cases without HR-HPV (19% vs 0.7%) (P = 0.001).  Cases with treatment failure had higher post-
LLETZ RLU HR-HPV values than cases without lesions (P = 0.001). In addition, cases with 
atypical squamous cells of undetermined significance or worse at the first post-LLETZ cytology 
had more residual or recurrent CIN2–3 than cases with normal cytology (50% vs 3%) (P = 0.001).
Surgical margins were involved in 75 cases (31%) cases, and uncertain in 31 (12.8%), 
making a total of 43.8%. The proportions of involvement of the different surgical margins are 
found in table 1. Statistically significant differences in the proportions of CIN 2–3 treatment 
failure were observed by margin status (P = 0.003), being higher in margins that had uncertain 
(19.4%), ecto(+)/endocervical(+) (16.7%), and ecto(-)/endocervical(+)  (9.1%) involvement. By 
contrast, ecto(+)/endocervical (-) and clear margins accounted for 2.4% and 1.5% of CIN2–3 
treatment failures, respectively. No difference in residual/ recurrent CIN2–3 was observed by 
glandular involvement, number of quadrants involved, or smoking status
Predictors of Treatment Failure by Survival and Univariate Logistic Analyses
Univariate logistic analysis showed the ORs related to CIN2–3 treatment failure. Women 
older than 35 years were at increased risk (OR = 5.45; 95% CI=1.18-25.15; P =0.011) compared 
to younger women. Margin involvement was significantly related to CIN2–3 treatment failure (P = 
0.004), with ORs of 13.20 (95% CI = 1.02-170.96) for  ecto(+)/endocervical(+) margins, 15.84 
(95% CI = 3.02-83.01 ) for uncertain margins, and 6.60 (95% CI =0.88-49.53 ) for ecto(-
)/endocervical(+) margins. Ecto(+)/endocervical(-) margins had a non-significant OR of  
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fold increased odds (OR =32; P = <0.001) of developing a recurrent or residual lesion than women 
with a negative result (Table S1 Supporting Information).The crude hazard ratios (HRs) for age, 
margin status, and first HR-HPV detection after LLETZ are presented in Table 2. Statistically 
significant worse treatment failure was observed among patients older than 35 years (HR = 5.53; 
95% CI =1.22-25.13; P =0.009), with involved margins (HR = 7.31; 95%; CI = 1.60–33.44; P = 
0.003), and with HR-HPV positivity (HR =30.58; 95% CI =3.80-246.20 ; P < 0.001). CIN2–3 
relapse appeared earlier in HR-HPV positive cases, which had a 30.5 fold higher risk of 
developing CIN2–3 in the next period of time than HR-HPV negative cases.  
Sensitivity and specificity analysis for the Predictors of Treatment Failure
Table 3 shows the sensitivity, specificity, PPV, NPV, and likelihood ratio for margins or 
HR-HPV as predictors of treatment failure after LLETZ. First, HR-HPV detection after treatment 
had a sensitivity of 88.8, a specificity of 80, and an NPV of 99.2. The addition of margins or 
cytology to the HR-HPV result did not substantially improve the diagnostic accuracy. 
 A significant difference was also observed in HR-HPV positivity in relation to margin 
status (P = 0.024). If we consider the margins involved, there was lower HR-HPV detection (3 
cases, 7.9%) in ecto(+)/endocervical(-) margins (P = 0.010) and higher HR-HPV positivity in 
uncertain margins (10 cases, 41.7%; P = 0.036). No differences were found in relation to HPV 
positivity for ecto(-)/endocervical (+) margins (Table S2 Supporting Information).
Kaplan–Meier Estimates
The Kaplan–Meier estimates for the failure rate by HR-HPV post-LLETZ status, margin 
status, and HR-HPV post-LLETZ status stratified by margins are shown in Figure 1 (a, b, and c, 
respectively). Women with HR-HPV positive post-LLETZ status (log-rank P < 0.001), involved 
margins (log-rank P = 0.002), and HR-HPV positivity and involved margins (log-rank P < 0.001) 
had a higher and earlier failure rate. Separate analysis of the different margin involvements shows 
differences in failure rates after LLETZ (P < 0.001), with higher failure rates for uncertain, ecto(-
)/endocervical(+), and ecto(+)/endocervical(+) margins (Figure S2 e. Supporting Information).
The results for HR-HPV post-LLETZ positivity stratified by margins show differences 
between the presence of clear margins (log-rank P = 0.025), ecto(+)/endocervical(-) margins (log-
rank P < 0.001), and uncertain margins (log-rank P = 0.011). All uncertain margins with HR-HPV 
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CIN2–3 treatment showed a favourable long-term outcome with treatment failure to CIN2–
3 in 13 cases (5.7%). More than 50% of lesions were diagnosed during the first 2 years after 
LLETZ, with 25% found after 51 months and one case after 212 months.
HR-HPV determined after LLETZ was a strong predictive factor for treatment failure (P < 
0.001) independently of the effect of margin involvement. CIN 2–3 relapse appeared earlier in 
HR-HPV positive cases, with a 30.5-fold higher risk to have CIN 2-–3 in the next period of time 
than HR-HPV negative cases. 
  As expected, women with involved margins presented recurrence more often than those 
with clear margins (HR = 7.31; P = 0.003), and the effect was independent of HPV status and age. 
Interestingly, the type of margin involvement seemed to predict treatment failure, particularly for 
those women with ecto(+)/endocervical(+) (16.7%) or uncertain margin involvement (19.4%). 
Being older than 35 years was another predictive factor of recurrence (P =0.009). 
Except for ecto(+)/endocervical(-) margins, involved margins were also associated with 
more HR- HPV positivity than clear margins (P = 0.024). Uncertain margins presented the highest 
HR-HPV positivity (41%), and ecto(+)/endocervical(-) the lowest positivity (7.9%).
Involved margins with HR-HPV positivity were associated with more recurrences than 
those that were negative for HR-HPV. Involved margins with HR-HPV negativity had less risk of 
recurrence. 
Strengths and Limitations
Our study has several strengths, not least of which are the inclusion of a large sample with 
restrictive inclusion criteria and a long follow-up at the same hospital. This allowed us to detect 
late relapse and to determine the real risk of cervical cancer and CIN. The analysis of factors 
associated with the time to CIN2–3 recurrence is another strength of our study. To the best of our 
knowledge, no previous authors have analysed the relationship of different margin types by HPV 
positivity and the time to CIN 2–3 recurrence. 
By contrast, the main study limitations are the retrospective nature and the fact that some 
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major limitation is that we combined CIN2 and CIN3 for the analysis of recurrence due to the 
small sample size. Another weakness is the large proportion of uncertain margins, which suggests 
moderate/poor reproducibility of margin assessment after LLETZ. Finally, the confidence interval 
of the results is wide due to the small number of positive cases. This suggests that the magnitude 
of the effect is uncertain. 
Interpretation
Post-treatment HR-HPV determination has clearly demonstrated a higher sensitivity and 
NPV than cytology or margins for detecting the residual or recurrent CIN (4)(10)(13).  In a meta-
analysis, HR-HPV showed a sensitivity of 91% and specificity of 83.8%.  The pre-test/post-test 
probability assessment demonstrated that a post-treatment positive HR-HPV increases the risk of 
treatment failure to 28.4%, and a negative HR-HPV reduces the risk to 0.8%(10). In our study, the 
univariate analysis showed that HR-HPV post LLETZ has an OR=32 of treatment failure.
Post- LLETZ HR-HPV was positive in 23.5% of cases, in line with the results of a previous 
meta-analysis (15). 
Our data show that margin involvement is a predictor of treatment failure (10)(16)(17). Two 
meta-analyses observed that CIN2–3 disease recurred in 18% of cases with involved margins 
versus 3% with clear margins(10) (16) . The relative risk of CIN2–3 recurrence after incomplete 
excision has also been reported to be  4.8 (10), observed in a meta-analysis of 97 studies. 
Our study showed that resection margins only had limited value in predicting treatment 
failure. These findings were consistent with the latter meta-analysis (10), which revealed that 
margins were 38% less sensitive than HR-HPV when predicting treatment failure.
In our series, specimens with involved margins and HR-HPV positivity recurred  more 
frequently than those with clear or involved margins negative for HR-HPV (Figure 1c, d). This 
pattern was observed in a study of CIN1 and CIN2–3 cases (11). 
We observed a lower risk of residual or recurrent CIN2–3 when the ecto(+)/endocervical(-) 
margin was involved, with a higher risk when there was involvement of the ecto(-
)/endocervical(+) or  ecto(+)/endocervical (+) margins. Similar results were reported in a meta-
analysis of 44,000 women(10). However, the lack of association of ecto(-)/endocervical(+) 
margins with residual or recurrent CIN2–3 in the present study was an unexpected finding. The 
available literature suggests that involvement of the endocervical margin implies an increased risk 
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were associated with treatment failure and had shorter time to recurrence, but this association was 
not significant, possibly because of the small number of cases.
Other unexpected findings were the high proportion of treatment failures and HPV 
positivity in uncertain margins. The cases of uncertain margins indicate that there was difficulty in 
the evaluation of the surgical specimen, due to epithelial detachment. The diathermy effect can 
cause thermal damage and detachment of the epithelium. This can lead to an increase in the 
number of uncertain margins, and an overestimation of involved margins. The association of 
uncertain margins with HPV and treatment failure could be related to the lower adhesive capacity 
of neoplastic epithelium, as for example, the expressions of E-cadherin and β-catenin are altered in 
CIN and affect epithelial cell adhesion. This altered expression increases with the severity of  CIN 
(18). Detached epithelium can hide a CIN2–3 lesion and may be related to the low reproducibility 
of margin assessment (10).
Our series shows that involvement of ecto(+)/endocervical(-) margins has lower rates of 
failure and HR-HPV positivity. Recent thinking suggests that the site of HPV infection affects the 
pattern of viral gene expression.  Infections are more likely to be productive  in the ectocervix, and 
more likely to be non-productive  in the endocervix (19)(20). For this reason, our results, and 
those of others, can be explained as a transient infection, different from that of endocervical 
infection.
Increasing age is also known to be a predictor of CIN2–3 treatment failure (4)(6)(21)(7),  
though it is not always observed (22). In the present study, we showed that patients older than 35 
years were at higher risk of CIN 2–3 recurrence and had shorter times to recurrence.
Conclusion
Women treated with LLETZ for CIN2–3 show favourable long-term clinical outcomes. 
Cases positive for HR-HPV recur earlier, as do those with involved margins and those in women 
older than 35 years. However, HR-HPV appears to be the strongest predictive factor for treatment 
failure. When margins are involved, recurrence tends to be more frequent when they are HR-HPV 
positive. Furthermore, the risk of treatment failure and the time to recurrence differs by the type of 
margin and HPV positivity, with ecto(+)/endocervical(-) margins showing the lowest treatment 
failure, and the other margins showing higher failure rates. 
We believe that HR-HPV and margin statuses can be used to stratify the post-LLETZ risk 
of recurrence and enable personalised management. This risk-based management has been used to 









margins present a lower risk of treatment failure and, given that risk increases with age, larger 
excisions could be indicated in older women. 
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TABLE 1. Follow up time, patient and surgical specimen characteristics. Patients treated with Large Loop Excision of 
the Transformation Zone (LLETZ) for Cervical Intraepithelial Neoplasia 2-3 (CIN2-3). 
PATIENT CHARACTERISTICS 
 
 Number of patients 
(%1) 









Follow up time (in months) Median (Min-Max) 
(IQ range) 
30.3 (2-257) 






Age (years) Median (Min-Max) 
Mean (SD) 
  35.5 (18-77) 














 2 (1.7) 
11 (8.7) 
0.020 
Parity  Nulliparous 
≤4 full-term births 
>4 full-term births 
Unknown 
  41 (16.9) 
170 (70.2) 
  14 (5.8) 





 0 (0.0) 
10 (5.9) 
 3 (21.4) 
 0 (0.0) 
 
0.016 




  83 (34.3) 




 9 (6.4) 
 4 (4.8) 
 0 (0.0) 
 
0.771 
HPV AND CITOLOGY RESULTS      




 42 (17.4) 




 1 (0.7) 
 8 (19.0) 
 4 (6.3) 
 
<0.001 
First RLU HR-HPV post-LLETZ (N=167) Median (Min-Max) 
IQ range 






First RLU HR-HPV post-LLETZ cat 
                                  
Negative <1                                                     
1-100                                                      
>100                                               
Unknown 
130 (53.7 ) 
26 (10.7 ) 
11 (4.6) 





              1  (0.8) 
               3 (11.5) 
                5 (45.5) 
                4  ( 5.3 ) 
<0.001 





  18 (7.4) 
  13 (5.4) 













     
Margin status  Clear 
Involved 
                           









  75 (31.0) 
 
  42 (17.4) 
  22 (9.1) 
    6 (2.5) 
4 (1.7) 
    1 (0.4) 
 
  31 (12.8) 












 2 (1.5) 
 4 (5.3) 
 
  1 (2.4) 
2 (9.1) 
1 (16.7) 
 0 (0.0) 
 0 (0.0) 
  








                            11 (4.5) 
   80 (33.1) 




 0 (0.0) 









  37 (15.3) 
  50 (20.7) 
  21 (8.7) 
  54 (22.3) 






 2 (5.4) 
 5 (10.0) 
 1 (4.8) 





Circumference of the cervical 










































TOTAL   242 (100.0) 229 (94.6) 13 (5.4)  
IQ Range: Interquartile range (25%-75%); 1: column percent; 2: row percent; 3: Fisher’s exact test P-value; $: ANOVA test P-value; &: Kruskal-
Wallis test P-value.Abbreviations: HSIL, high-grade intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; ASCUS, atypical 
squamous cells of undetermined significance; HR-HPV, high-risk human papillomavirus; RLU, relative lights units. CIN, Cervical intraepithelial 
neoplasia. Circumference and length of the cervical specimen determined according to the 2011 International Federation of Cervical Pathology 
and Colposcopy Colposcopic Terminology.(24) Length is the distance from the distal to the proximal margin of the cervical specimen. 
Circumference is the perimeter of the excised specimen. 
TABLE 2: Univariate Cox Regression Analysis of the factors associated to residual/ recurrent Cervical Intraepithelial 
eoplasia 2-3 (CIN2-3) after Loop Electrosurgical Excision Procedure (LLETZ) 
CI: Confidence interval; *: 97.5% CI; P-value1:  log-likelihood ratio test P-value; |: No recurrences observed in the 
category; Endo(+) contains Ecto(-)/Endo(+) and Ecto(+)/Endo(+).
Characteristics 
Total CIN 2-3  Univariate analysis 
N N % [ 95%CI]  HR [ 95% CI] P-value1 
Age       1.0 [0.99-1.1] 0.113 
Age (categorized at 35 
years)  
       0.009 
<35 yo 116 
126 
2 1.7 [0.2-6.1]  Ref.   
35+ yo 11 8.7 [4.4-15.1]  5.5 [1.2-25.1]  
Margin status         0.001 








2 1.5 [0.2-5.3]  Ref.   
Ecto+/Endo- 1 2.4 [0.1-12.6]  1.7 [0.2-19.3]  
 Ecto-/Endo+ 2 9.1 [1.1-29.2]  5.7 [0.8-41.3]  
Deep 0 0.0 [0.0-97.5*]  -| -  
Ecto+/Endo+ 1 16.7 [0.4-64.1]  10.4 [0.9-118.4]  
All 0 0.0 [0.0-60.2*]  -| -  
Uncertain 6 19.4 [7.5-37.5]  19.4 [3.8-99.5]  
Unknown 1       
Margin status (Endo 
category)  
     
  0.003 







2 1.5 [0.2-5.3]  Ref.   
Ecto+/Endo- 1 2.4 [0.1-12.6]  1.7 [0.2-19.3]  
Endo+ 3 10.7 [2.3-28.2]  6.7 [1.1-41.2]  
Deep 0 0.0 [0.0-97.5*]  -| -  
All 0 0.0 [0.0-60.2*]  -| -  
Uncertain 6 19.4 [7.5-37.5]  19.5 [3.8-99.7]  
Unknown 1       
Margin status (Clear vs 
Involved) 
     
  0.003 
Clear 134 2 1.5 [0.2-5.3]  Ref.   
Involved 106 10 9.4 [4.6-16.7]  7.31 [1.6-33.4]  
Unknown 2 0       
Margin status (Clear vs 
Involved vs Uncertain) 
     
  <0.001 
Clear 134 2 1.5 [0.2-5.3]  Ref.   
Involved 75 4 5.3 [1.5-13.1]  3.7 [0.7-20.4]  
Uncertain 31 6 19.4 [7.5-37.5]  20.3 [3.9-105.3]  
Unknown 2 1       




      <0.001 
Negative 1 0.7 [0.0-4.0]  Ref.   
Positive 8 19.0 [8.6-34.1]  30.6 [3.8-246.2]  
Unknown 11       
First RLU HPV post-LLETZ 167     1.0 [0.999-1.0] 0.374 
First RLU HPV post-LLETZ 
cat    
  
  <0.001 
Negative 130 1 0.8 [0.0-4.2]  Ref.   
1-100 26 3 11.5 [2.4-30.2]  14.1 [1.5-136.1]  
>100 11 5 45.5 [16.7-76.6]  190.2 [19.4-1832.8]  
Unknown 75 4       
Parity        0.033 
Nulliparous 41 0 0.0 [0.0-8.6*]  -|   
<4 full-term births 170 10 5.9 [2.9-10.6]  0.3 [0.1-0.97]  
4+ full-term births 14 3 21.4 [4.7-50.8]  Ref. -  
Unknown 17 0       
Total 242 13 19.8 [15.0-25.4]     
 
TABLE 3. 
 Sensitivity, specificity, positive predicted value, negative predicted value, positive likelihood ratio, of margin status, first HR-HPV detection after Large Loop excision of the 
Transformation Zone (LLETZ) with regard of residual/recurrent Cervical Intraepithelial Neoplasia 2-3 (CIN 2-3). 
 















Margins                                                                                                                                                                                                             
                               Involved or uncertain                                                                                                   
Involved (without uncertain)                                                                                                                                                                    
10/12=83.3 















Margins      <0.001 
Ecto(+)/Endocervical(-)  1/12=8.3 187/228=82.0 1/42=2.3 187/198=94.4 0.4 0.697 
Ecto(-)/Endocervical(+) 2/12=16.6 208/228=91.2 2/22=9.0 208/218=95.4 1.9 0.303 
Other* 1/12=8.3 218/228=95.6 1/11=9.0 218/229=95.2 1.9 0.438 
Uncertain 6/12=50.0 203/228=89.0 6/31=19.3 203/209=97.1 4.5 0.002 
HR-HPV detection after LLETZ 8/9=88.8 136/170=80.0 8/42=19.0 136/137=99.2 4.4 <0.001 
Margins AND First HR-HPV detection 
after LLETZ 
      
Clear&HPV- 
Involved or uncertain&HPV-  






















Clear&HPV+1 1/9=11.1 149/170=87.6 1/22=4.5 149/157=94.9 0.0 1.000 
Involved or uncertain&HPV+1 7/9=77.7 157/170=92.3 7/20=35.0 157/159=98.7 10.2  <0.001 
Involved (without uncertain)&HPV+1 2/9=22.2 162/170=95.2 2/10=20.0 162/169=95.8 4.7 0.082 
Uncertain&HPV+1 5/9=55.5 165/170=97.0 5/10=50.0 165/169=97.6 18.8 <0.001 
Margins OR First HR-HPV detection 
after LLETZ 
      
ClearOR HPV+1 8/9=88.9 65/170=38.2 8/113=7.1 65/66=98.5 1.4 0.157 
Involved or uncertain OR HPV+1 9/9=100.0 71/170=41.8 9/108=8.3 71/71=100 1.7 0.012 
Involved(without incertain)ORHPV+1 4/9=44.4 90/170=52.9 4/84=4.8 90/95=94.7 0.9 1.000 
UncertainORHPV+1 8/9=88.9 122/170=71.8 8/56=14.3 122/123=99.2 3.2 <0.001 
       
Se: Sensitivity; Sp: Specificity; PPV: Positive predicted value; NPV: Negative predicted value; LR+: Positive likelihood ratio; 1: Considering as negative combinations of -/+, and 
+/- and -/-, and as positive only combination of +/+;  Numbers may not add up to 100  due to missing values; LLETZ: Large Loop Excision of the Transformation Zone.  HR-




     Panel a           Panel b 
                              
           Panel c                                                                                            Panel d  
FIGURE 1: Cervical Intraepithelial Neoplasia (CIN2-3) Failure Rate after Large Loop Excision of the Transformation Zone (LLETZ) by first high-risk human papillomavirus (HR-
HPV) post LLETZ, by margin status, and by margin involvement stratified by HR-HPV status. Panel a: Kaplan-Meier curve for CIN 2-3 Failure Rate after LLETZ by HR-HPV post 
treatment (P-Logrank<0.001). Panel b: Kaplan-Meier curve for CIN 2-3 Failure Rate after LLETZ by margin status (P-Logrank<0.001). Panel c: Kaplan-Meier curve for CIN 2-3 
Failure rate after LLETZ by margins status for positive first HR-HPV post-LLETZ (P-Logrank=0.002). Panel d: Kaplan-Meier curve for CIN 2-3 Failure rate after LLETZ by margins 
status for negative first HR-HPV post-LLETZ (P-Logrank=0.40).  
